Loss of CCM3 impairs DLL4-Notch signalling: Implication in endothelial angiogenesis and in inherited cerebral cavernous malformations

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 3, 2013, Pages 407-418

  You, Chao ^a,b   Erol Sandalcioglu, Ibrahim ^a   Dammann, Philipp ^a   Felbor, Ute ^c   Sure, Ulrich ^a   Zhu, Yuan ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Angiogenesis; CCM3 PDCD10; Cerebral cavernous malformation; DLL4 Notch signalling; Endothelium

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DLL4 PROTEIN, HUMAN; HES1 PROTEIN, HUMAN; HEY2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; NOTCH RECEPTOR; NOTCH4 PROTEIN, HUMAN; ONCOPROTEIN; PDCD10 PROTEIN, HUMAN; REPRESSOR PROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; BRAIN HEMANGIOMA; CELL ADHESION; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CHILD; DRUG ANTAGONISM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULARIZATION; WESTERN BLOTTING;

ADULT; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHILD; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC PREDISPOSITION TO DISEASE; HEMANGIOMA, CAVERNOUS, CENTRAL NERVOUS SYSTEM; HOMEODOMAIN PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NOTCH; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

INVERTEBRATA; VERTEBRATA;

EID: 84875782704     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12022     Document Type: Article

References (48)

1. Riant F, Bergametti F, Ayrignac X, et al. Recent insights into cerebral cavernous malformations: the molecular genetics of CCM. FEBS J. 2010; 277: 1070-5.
2. Bergametti F, Denier C, Labauge P, et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet. 2005; 76: 42-51.
3. Tanriover G, Boylan AJ, Diluna ML, et al. PDCD10, the gene mutated in cerebral cavernous malformation 3, is expressed in the neurovascular unit. Neurosurgery. 2008; 62: 930-8; discussion 8.
4. Petit N, Blecon A, Denier C, et al. Patterns of expression of the three cerebral cavernous malformation (CCM) genes during embryonic and postnatal brain development. Gene Expr Patterns. 2006; 6: 495-503.
5. Louvi A, Chen L, Two AM, et al. Loss of cerebral cavernous malformation 3 (Ccm3) in neuroglia leads to CCM and vascular pathology. Proc Natl Acad Sci USA. 2011; 108: 3737-42.
6. Denier C, Labauge P, Bergametti F, et al. Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol. 2006; 60: 550-6.
7. Gault J, Sain S, Hu LJ, et al. Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery. 2006; 59: 1278-84; discussion 84-5.
8. Zhu Y, Wu Q, Xu JF, et al. Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations. Neurosurg Focus. 2010; 29: E1. Doi: 10.3171/2010.5.FOCUS1090.
9. Schleider E, Stahl S, Wüstehube J, et al. Evidence for anti-angiogenic and pro-survival functions of the cerebral cavernous malformation protein 3. Neurogenetics. 2010; 12: 83-6.
10. Chan AC, Drakos SG, Ruiz OE, et al. Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice. J Clin Invest. 2011; 121: 1871-81.
11. He Y, Zhang H, Yu L, et al. Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal. 2010; 3: ra26. Doi: 10.1126/scisignal.2000722
12. Yoruk B, Gillers BS, Chi NC, et al. Ccm3 functions in a manner distinct from Ccm1 and Ccm2 in a zebrafish model of CCM vascular disease. Dev Biol. 2011; 362: 121-31.
13. Voss K, Stahl S, Schleider E, et al. CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics. 2007; 8: 249-56.
14. Stahl S, Gaetzner S, Voss K, et al. Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Hum Mutat. 2008; 29: 709-17.
15. Fidalgo M, Fraile M, Pires A, et al. CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell orientation. J Cell Sci. 2010; 123: 1274-84.
16. Zheng X, Xu C, Di Lorenzo A, et al. CCM3 signaling through sterile 20-like kinases plays an essential role during zebrafish cardiovascular development and cerebral cavernous malformations. J Clin Invest. 2010; 120: 2795-804.
17. Ma X, Zhao H, Shan J, et al. PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway. Mol Biol Cell. 2007; 18: 1965-78.
18. Ceccarelli DF, Laister RC, Mulligan VK, et al. CCM3/PDCD10 heterodimerizes with germinal center kinase III (GCKIII) proteins using a mechanism analogous to CCM3 homodimerization. J Biol Chem. 2011; 286: 25056-64.
19. Hilder TL, Malone MH, Bencharit S, et al. Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res. 2007; 6: 4343-55.
20. Fidalgo M, Guerrero A, Fraile M, et al. The adaptor protein cerebral cavernous malformation 3 (CCM3) mediates phosphorylation of the cytoskeletal proteins Ezrin/Radixin/Moesin by Mammalian Ste20-4 to protect cells from oxidative stress. J Biol Chem. 2012; 287: 11556-65.
21. Li X, Zhang R, Zhang H, et al. Crystal structure of CCM3, a cerebral cavernous malformation protein critical for vascular integrity. J Biol Chem. 2010; 285: 24099-107.
22. Kleaveland B, Zheng X, Liu JJ, et al. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat Med. 2009; 15: 169-76.
23. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006; 7: 678-89.
24. Gridley T. Notch signaling in vascular development and physiology. Development. 2007; 134: 2709-18.
25. Kume T. Novel insights into the differential functions of Notch ligands in vascular formation. J Angiogenes Res. 2009; 1: 8-16.
26. Hellstrom M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007; 445: 776-80.
27. Lobov IB, Cheung E, Wudali R, et al. The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow. Blood. 2011; 117: 6728-37.
28. Whitehead KJ, Plummer NW, Adams JA, et al. Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development. 2004; 131: 1437-48.
29. Wüstehube J, Bartol A, Liebler SS, et al. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci USA. 2010; 107: 12640-5.
30. Zhu Y, Wu Q, Fass M, et al. In vitro characterization of the angiogenic phenotype and genotype of the endothelia derived from sporadic cerebral cavernous malformations (CCMs). Neurosurgery. 2011; 69: 722-32.
31. Harrington LS, Sainson RC, Williams CK, et al. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res. 2008; 75: 144-54.
32. Pagenstecher A, Stahl S, Sure U, et al. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet. 2009; 18: 911-8.
33. Zhu Y, Wloch A, Wu Q, et al. Involvement of PTEN promoter methylation in cerebral cavernous malformations. Stroke. 2009; 40: 820-6.
34. Nakatsu MN, Sainson RC, Aoto JN, et al. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res. 2003; 66: 102-12.
35. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006; 444: 1083-7.
36. Moriarity JL, Wetzel M, Clatterbuck RE, et al. The natural history of cavernous malformations: a prospective study of 68 patients. Neurosurgery. 1999; 44: 1166-71; discussion 72-3.
37. Goitre L, Balzac F, Degani S, et al. KRIT1 regulates the homeostasis of intracellular reactive oxygen species. PLoS ONE. 2010; 5: e11786. Doi: 10.1371/journal.pone.0011786.
38. Bheeshmachar G, Purushotaman D, Sade H, et al. Evidence for a role for notch signaling in the cytokine-dependent survival of activated T cells. J Immunol. 2006; 177: 5041-50.
39. Hellstrom M, Phng LK, Gerhardt H. VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh Migr. 2007; 1: 133-6.
40. Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med. 2008; 14: 1236-46.
41. Suchting S, Freitas C, le Noble F, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA. 2007; 104: 3225-30.
42. Lobov IB, Renard RA, Papadopoulos N, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA. 2007; 104: 3219-24.
43. Williams CK, Li JL, Murga M, et al. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006; 107: 931-9.
44. Hainaud P, Contreres JO, Villemain A, et al. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res. 2006; 66: 8501-10.
45. Hashimoto T, Zhang XM, Chen BY, et al. VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development. 2006; 133: 2201-10.
46. Giuliani N, Lunghi P, Morandi F, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia. 2004; 18: 628-35.
47. Breslin JW, Pappas PJ, Cerveira JJ, et al. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol. 2003; 284: H92-100. Doi: 10.1152/ajpheart.00330.2002.
48. Narasimhan P, Liu J, Song YS, et al. VEGF Stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. Stroke. 2009; 40: 1467-73.